Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation;Caracterización de las concentraciones de fenitoína libre en pacientes en la unidad de cuidado neurointensivo usando la ecuación revisada de Winter-Tozer

Annals of Pharmacotherapy

Volumn 47, Issue 5, 2013, Pages 628-636

  Kane, Sean P ^a,b   Bress, Adam P ^a   Tesoro, Eljim P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; PHENYTOIN;

ADULT; ANALYTICAL ERROR; ARTICLE; COHORT ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; WINTER TOZER EQUATION;

EID: 84877091535     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R651     Document Type: Article

References (18)

1. Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm 1977;5:579-96.
2. von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy 2008;28:1391-400.
3. May TW, Rambeck B, Jürges U, Blankenhorn V, Jürgens U. Comparison of total and free phenytoin serum concentrations measured by high-performance liquid chromatography and standard TDx assay: implications for the prediction of free phenytoin serum concentrations. Ther Drug Monit 1998;20:619-23.
4. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999;123:822-3.
5. Winter MG, Tozer TN. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:1-44.
6. Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997;31:279-84.
7. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. DICP 1989;23:64-8.
8. Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J 2009;50:517-20.
9. Boucher BA, Rodman JH, Fabian TC, et al. Disposition of phenytoin in critically ill trauma patients. Clin Pharm 1987;6:881-7.
10. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit 1994;16:139-44.
11. Beck DE, Farringer JA, Ravis WR, Robinson CA. Accuracy of three methods for predicting concentrations of free phenytoin. Clin Pharm 1987;6:888-94.
12. Mlynarek ME, Peterson EL, Zarowitz BJ. Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother 1996;30:219-23.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
15. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14-20.
16. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician 1983;32:307-17.
17. Allison TB, Comstock TJ. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia. Ther Drug Monit 1988;10:376-81.
18. Krasowski MD, Penrod LE. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak 2012;12:7.